Stocktoria
Bionano Genomics, Inc. BNGO
Bionano Genomics, Inc. financials (annual)
Bars are annual figures from 2017 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $28.5M | $30.8M | $36.1M | $27.8M | $18.0M | $8.5M | $10.1M | $12.0M | $9.5M |
| R&D expense | $11.4M | $24.8M | $54.0M | $49.0M | $22.5M | $10.3M | $9.1M | $9.5M | $12.0M |
| SG&A expense | $35.1M | $51.9M | $92.8M | $88.6M | $58.5M | $31.1M | $20.2M | $14.2M | $14.1M |
| Operating income | -$33.3M | -$104.0M | -$215.2M | -$131.7M | -$77.1M | -$38.6M | -$25.9M | -$20.4M | -$23.2M |
| Interest expense | — | — | $5.1M | $298,000 | $927,000 | $2.5M | $2.3M | $1.4M | $590,927 |
| Income tax | $67,000 | $33,000 | $62,000 | $1.9M | -$5.7M | $29,000 | $21,048 | $15,511 | $18,552 |
| Net income | -$26.4M | -$112.0M | -$232.5M | -$132.6M | -$72.4M | -$41.1M | -$29.8M | -$18.5M | -$23.4M |
| EPS (diluted) | $-4.85 | $-88.13 | $-408.60 | $-4.58 | $-0.26 | — | — | — | — |
| Operating cash flow | -$16.3M | -$68.9M | -$125.2M | -$124.8M | -$71.9M | -$38.3M | -$29.5M | -$19.9M | -$20.8M |
| Free cash flow | — | — | — | — | — | -$38.3M | -$29.6M | -$20.3M | -$21.8M |
| Cash & equivalents | $3.0M | $9.2M | $17.9M | $5.1M | $24.6M | $38.4M | $17.3M | $16.5M | $1.0M |
| Inventory | $7.8M | $13.3M | $27.6M | $29.8M | $12.4M | $3.3M | $3.4M | $1.1M | $1.7M |
| Total assets | $73.6M | $76.7M | $214.4M | $307.5M | $377.1M | $60.5M | $30.2M | $24.8M | $10.1M |
| Total liabilities | $29.2M | $41.3M | $118.2M | $58.1M | $40.0M | $25.4M | $26.6M | $14.7M | $17.4M |
| Shareholders' equity | $44.4M | $35.4M | $96.2M | $249.4M | $337.1M | $35.1M | $3.6M | $10.1M | -$50.2M |
Growth · year-over-year · Revenue CAGR 14.7%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -7.4% | -14.8% | +29.9% | +54.6% | +111.5% | -16.1% | -15.6% | +26.3% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.